Enveric Biosciences, Inc. (ENVB) Key Statistics & Financial Ratios

Enveric Biosciences, Inc. (ENVB) — Price $1.49 HealthcareBiotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Enveric Biosciences, Inc. (ENVB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application.

Stock Data

Price$1.49
Market Cap$1M
Enterprise Value-$7.4M
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.09
Price / Book0.74
P/S0.00
EV/EBITDA0.86
EV/Sales0.00
EV/FCF0.87
P/FCF-0.10
Earnings Yield-146.93%
FCF Yield-962.42%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-168.05%
Return on Assets-97.60%
Return on Invested Capital-107.99%
Return on Capital Employed-107.99%

Financial Health

Current Ratio10.21
Quick Ratio10.21
Cash Ratio9.63
Debt / Equity0.00
Debt / Assets0.00%
Net Debt / EBITDA0.97
Interest Coverage-10329.56
Piotroski F-Score3
Altman Z-Score-35.49

Per-Share Data

Revenue per share0.00
Book Value per share2.03
Cash per share2.08
FCF per share-2.15
Tangible Book Value per share2.03
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy3
Hold1
Sell0
Strong Sell0
Total analysts4
Avg rating (1-5)0.75

Related companies: AZTR · HEPA · INDP · JSPR · ONCO · SCNI · SLRX

Explore sector: Healthcare · Biotechnology

More sections of ENVB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks